Jackson Square Capital LLC Sells 3,592 Shares of Stryker Co. (NYSE:SYK)

Jackson Square Capital LLC decreased its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 28.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,107 shares of the medical technology company's stock after selling 3,592 shares during the quarter. Jackson Square Capital LLC's holdings in Stryker were worth $3,290,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Blake Schutter Theil Wealth Advisors LLC acquired a new position in shares of Stryker in the 3rd quarter valued at $402,000. Forte Capital LLC ADV boosted its stake in Stryker by 1.8% in the 3rd quarter. Forte Capital LLC ADV now owns 5,407 shares of the medical technology company's stock worth $1,953,000 after purchasing an additional 93 shares during the period. Two Point Capital Management Inc. raised its stake in shares of Stryker by 1.1% in the 3rd quarter. Two Point Capital Management Inc. now owns 21,833 shares of the medical technology company's stock valued at $7,887,000 after purchasing an additional 245 shares during the period. Consilium Wealth Advisory LLC bought a new stake in shares of Stryker in the third quarter valued at about $512,000. Finally, Gordian Advisors LLC bought a new position in shares of Stryker during the third quarter worth about $298,000. Institutional investors own 77.09% of the company's stock.

Insider Activity at Stryker

In other Stryker news, VP M Kathryn Fink sold 7,347 shares of the firm's stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $366.98, for a total transaction of $2,696,202.06. Following the completion of the transaction, the vice president now owns 10,042 shares in the company, valued at approximately $3,685,213.16. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Stryker news, VP M Kathryn Fink sold 7,347 shares of the stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total transaction of $2,696,202.06. Following the completion of the sale, the vice president now directly owns 10,042 shares in the company, valued at approximately $3,685,213.16. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Viju Menon sold 600 shares of the business's stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total value of $213,000.00. Following the completion of the transaction, the insider now directly owns 9,069 shares in the company, valued at $3,219,495. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 10,068 shares of company stock worth $3,693,972 over the last three months. Company insiders own 5.50% of the company's stock.

Stryker Price Performance

NYSE:SYK traded up $0.82 on Thursday, hitting $369.84. The company had a trading volume of 269,521 shares, compared to its average volume of 1,252,896. The firm has a 50 day moving average of $360.91 and a two-hundred day moving average of $345.12. The stock has a market capitalization of $140.99 billion, a price-to-earnings ratio of 39.55, a PEG ratio of 2.77 and a beta of 0.91. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. Stryker Co. has a 52 week low of $266.93 and a 52 week high of $376.04.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, beating the consensus estimate of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The firm had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. During the same period last year, the company earned $2.46 earnings per share. The business's quarterly revenue was up 11.9% on a year-over-year basis. On average, research analysts anticipate that Stryker Co. will post 12.06 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on SYK. UBS Group boosted their price objective on shares of Stryker from $366.00 to $370.00 and gave the stock a "neutral" rating in a research report on Wednesday, October 30th. Truist Financial boosted their target price on Stryker from $370.00 to $380.00 and gave the stock a "hold" rating in a report on Wednesday, October 30th. Citigroup upped their target price on Stryker from $406.00 to $411.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. Morgan Stanley lifted their target price on Stryker from $345.00 to $350.00 and gave the stock an "equal weight" rating in a report on Monday, July 15th. Finally, Robert W. Baird lifted their price objective on shares of Stryker from $378.00 to $405.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 30th. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $393.65.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.